Georgia Institute of Technology

The University of Michigan is crushing it in Money's latest rankings, standing out for affordability, quality, and overall value. For in-state students, the net cost of a degree before financial aid hovers around $102,000—cheaper than about 650 other schools on the list. And with a sky-high 93% quality rating, it’s clear Michigan isn’t just a bargain; it’s a top-tier education.

Editor’s Note: If you’re weighing college options, this is a big deal. Michigan’s combo of lower costs and high-quality academics makes it a standout choice, especially for in-state students. It’s a rare win in the "you-get-what-you-pay-for" debate—proof that elite education doesn’t always come with elite sticker shock.

Chewy, the popular online pet retailer, is snagging a bigger slice of the pet retail market as spending on pets rebounds, according to a Bank of America report. Basically, more pet owners are opening their wallets for their furry friends, and Chewy’s benefiting from that trend.

Editor’s Note: Pet spending is bouncing back after some rocky economic patches, and Chewy’s growth shows how e-commerce is still a major player in the pet industry. If you’ve ever splurged on your dog’s fancy treats or auto-ship cat food, you’re part of the trend—people aren’t cutting back on their pets, even when budgets are tight. For investors, it’s a sign that pet retail is resilient, and for shoppers, it means more competition (and maybe better deals) in the pet supply space.

UnitedHealth is reportedly facing an investigation that will zero in on its pharmacy benefit manager (PBM) division, according to a report by Capital Forum. While details are still emerging, this suggests regulators are scrutinizing potential issues in how the company manages drug pricing and benefits—a hot-button topic in healthcare.

Editor’s Note: PBMs are middlemen in the drug supply chain, and their practices often come under fire for lack of transparency or driving up costs. If UnitedHealth’s PBM unit is under investigation, it could signal broader regulatory pressure on the industry—and potentially ripple effects for drug prices and insurance plans. For everyday folks, this might mean more scrutiny on why medications cost so much.

Tesla's much-hyped robotaxi, which is supposed to be a fully autonomous ride-hailing vehicle, has been caught making a bunch of driving errors during tests in Texas. From awkward lane changes to hesitating at intersections, the footage shows the tech isn’t quite ready for prime time—despite Elon Musk’s bold promises.

Editor’s Note: Self-driving cars are supposed to be the future, but this report is a reality check. If Tesla—one of the biggest names in the game—is still struggling with basic driving scenarios, it raises questions about how soon (or if) fully autonomous taxis will actually hit the streets safely. For investors, regulators, and anyone who’s been excited about hopping into a driverless car, this is a sign that the tech still has a long road ahead.

An independent director at a bank, Beia, just scooped up over $55,000 worth of shares in the company. That’s a pretty solid vote of confidence—when insiders buy, it often signals they believe the stock is undervalued or poised for growth.

Editor’s Note: Insider purchases like this can be a green flag for investors. If someone with a front-row seat to the bank’s health is putting their own money in, it might hint at brighter days ahead. Of course, it’s not a guarantee, but it’s the kind of move that makes people perk up and take notice.